|
CH653021A5
(fr)
|
1981-04-24 |
1985-12-13 |
Delalande Sa |
Derives piperidino, piperazino et homopiperazino, n-substitues par un groupe heterocyclique aromatique, leur procede de preparation et composition therapeutique les contenant.
|
|
IL73534A
(en)
|
1983-11-18 |
1990-12-23 |
Riker Laboratories Inc |
1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
|
|
AU600575B2
(en)
|
1987-03-18 |
1990-08-16 |
Sb2, Inc. |
Altered antibodies
|
|
WO1990014844A2
(en)
|
1989-06-06 |
1990-12-13 |
Neorx Corporation |
Sugars as cleavable linkers for the delivery and release of agents in native form
|
|
US5650150A
(en)
|
1990-11-09 |
1997-07-22 |
Gillies; Stephen D. |
Recombinant antibody cytokine fusion proteins
|
|
US5389640A
(en)
|
1991-03-01 |
1995-02-14 |
Minnesota Mining And Manufacturing Company |
1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
|
|
DE69434279T2
(de)
*
|
1993-12-09 |
2006-04-06 |
Centro De Inmunologia Molecular |
Impfstoff, der einen menschlichen autologenen epidermalen Wachstumsfaktor enthält und dessen Verwendung
|
|
EP0894797A4
(en)
|
1997-01-09 |
2001-08-16 |
Terumo Corp |
NEW AMID DERIVATIVES AND INTERMEDIATES ON YOUR SYNTHESIS
|
|
ZA9811162B
(en)
*
|
1997-12-12 |
2000-06-07 |
Genentech Inc |
Treatment with anti-ERBB2 antibodies.
|
|
US20090208418A1
(en)
*
|
2005-04-29 |
2009-08-20 |
Innexus Biotechnology Internaltional Ltd. |
Superantibody synthesis and use in detection, prevention and treatment of disease
|
|
US20020155108A1
(en)
|
1998-05-04 |
2002-10-24 |
Biocrystal, Ltd. |
Method for ex vivo loading of antigen presenting cells with antigen, and a vaccine comprising the loaded cells
|
|
SE513217C2
(sv)
|
1999-06-03 |
2000-07-31 |
Jan Folke Wallenius |
Förfarande och anordning för att under färd bestämma friktionen mellan vägbanan och ett fordons hjul
|
|
FI107193B
(fi)
|
1999-06-03 |
2001-06-15 |
Rouvari Oy R |
Mittausanturi
|
|
GB2354828A
(en)
|
1999-06-04 |
2001-04-04 |
Cheong Cheun Edmund Choi |
Apparatus and method for testing an impervious surface
|
|
US6451810B1
(en)
|
1999-06-10 |
2002-09-17 |
3M Innovative Properties Company |
Amide substituted imidazoquinolines
|
|
US6541485B1
(en)
|
1999-06-10 |
2003-04-01 |
3M Innovative Properties Company |
Urea substituted imidazoquinolines
|
|
US6331539B1
(en)
|
1999-06-10 |
2001-12-18 |
3M Innovative Properties Company |
Sulfonamide and sulfamide substituted imidazoquinolines
|
|
US6756382B2
(en)
|
1999-06-10 |
2004-06-29 |
3M Innovative Properties Company |
Amide substituted imidazoquinolines
|
|
US6573273B1
(en)
|
1999-06-10 |
2003-06-03 |
3M Innovative Properties Company |
Urea substituted imidazoquinolines
|
|
EP2264072A1
(en)
|
2000-04-13 |
2010-12-22 |
The Rockefeller University |
Enhancement of antibody-mediated cytotoxicity.
|
|
WO2001097843A2
(en)
|
2000-06-22 |
2001-12-27 |
University Of Iowa Research Foundation |
Methods for enhancing antibody-induced cell lysis and treating cancer
|
|
CN1549726A
(zh)
*
|
2000-07-31 |
2004-11-24 |
耶鲁大学 |
先天性免疫系统指导的疫苗
|
|
MXPA03003632A
(es)
|
2000-10-24 |
2003-09-10 |
Immunex Corp |
Metodo para tratamiento de tumores usando terapia de combinacion.
|
|
US20060142202A1
(en)
|
2000-12-08 |
2006-06-29 |
3M Innovative Properties Company |
Compositions and methods for targeted delivery of immune response modifiers
|
|
US20020110840A1
(en)
|
2000-12-08 |
2002-08-15 |
3M Innovative Properties Company |
Screening method for identifying compounds that selectively induce interferon alpha
|
|
EP1719511B1
(en)
|
2001-11-16 |
2008-12-10 |
3M Innovative Properties Company |
N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide, a pharmaceutical composition comprising the same and use thereof
|
|
DK1450804T3
(da)
|
2001-11-29 |
2009-01-05 |
3M Innovative Properties Co |
Farmaceutiske formulelringer, der omfatter et immunsvarmodificerende middel
|
|
US6677349B1
(en)
|
2001-12-21 |
2004-01-13 |
3M Innovative Properties Company |
Sulfonamide and sulfamide substituted imidazoquinolines
|
|
PT3483183T
(pt)
|
2002-03-01 |
2021-06-02 |
Immunomedics Inc |
Imunoconjugado compreendendo anticorpos rs7 humanizados
|
|
ATE488246T1
(de)
|
2002-08-15 |
2010-12-15 |
3M Innovative Properties Co |
Immunstimulatorische zusammensetzungen und verfahren zur stimulierung einer immunantwort
|
|
US6924154B2
(en)
|
2002-08-20 |
2005-08-02 |
Quest Diagnostics Investments Incorporated |
Hydrophilic chemilumescent acridinium labeling reagents
|
|
US20040101909A1
(en)
|
2002-08-20 |
2004-05-27 |
Hema-Quebec, 2535 Boul. Laurier, Ste-Foy, Quebec, Canada G1V 4M3 |
Purification of polyreactive autoantibodies and uses thereof
|
|
EP1542688A4
(en)
|
2002-09-26 |
2010-06-02 |
3M Innovative Properties Co |
1H-imidazo dimers
|
|
AU2003287316A1
(en)
|
2002-12-11 |
2004-06-30 |
3M Innovative Properties Company |
Assays relating to toll-like receptor activity
|
|
AU2003287324A1
(en)
|
2002-12-11 |
2004-06-30 |
3M Innovative Properties Company |
Gene expression systems and recombinant cell lines
|
|
US7091214B2
(en)
|
2002-12-20 |
2006-08-15 |
3M Innovative Properties Co. |
Aryl substituted Imidazoquinolines
|
|
EP1578419A4
(en)
|
2002-12-30 |
2008-11-12 |
3M Innovative Properties Co |
IMMUNOSTIMULATING COMBINATIONS
|
|
US7375180B2
(en)
|
2003-02-13 |
2008-05-20 |
3M Innovative Properties Company |
Methods and compositions related to IRM compounds and Toll-like receptor 8
|
|
EP1599726A4
(en)
|
2003-02-27 |
2009-07-22 |
3M Innovative Properties Co |
SELECTIVE MODULATION OF TLR-MEDIATED BIOLOGICAL ACTIVITY
|
|
EP1613956A2
(en)
|
2003-03-25 |
2006-01-11 |
3M Innovative Properties Company |
Selective activation of cellular activities mediated through a common toll-like receptor
|
|
EP1617872A4
(en)
|
2003-04-10 |
2011-09-07 |
3M Innovative Properties Co |
METHODS AND COMPOSITIONS FOR ENHANCING AN IMMUNE RESPONSE
|
|
US20040265351A1
(en)
|
2003-04-10 |
2004-12-30 |
Miller Richard L. |
Methods and compositions for enhancing immune response
|
|
WO2004108072A2
(en)
|
2003-04-10 |
2004-12-16 |
3M Innovative Properties Company |
Delivery of immune response modifier compounds using metal-containing particulate support materials
|
|
US20040214851A1
(en)
|
2003-04-28 |
2004-10-28 |
3M Innovative Properties Company |
Compositions and methods for induction of opioid receptors
|
|
US8088387B2
(en)
|
2003-10-10 |
2012-01-03 |
Immunogen Inc. |
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
|
|
MY157827A
(en)
|
2003-06-27 |
2016-07-29 |
3M Innovative Properties Co |
Sulfonamide substituted imidazoquinolines
|
|
US20050070460A1
(en)
|
2003-08-05 |
2005-03-31 |
3M Innovative Properties Company |
Infection prophylaxis using immune response modifier compounds
|
|
PL1653959T3
(pl)
|
2003-08-14 |
2015-10-30 |
3M Innovative Properties Co |
Modyfikatory odpowiedzi immunologicznej modyfikowane lipidami
|
|
WO2005019429A2
(en)
|
2003-08-22 |
2005-03-03 |
Potentia Pharmaceuticals, Inc. |
Compositions and methods for enhancing phagocytosis or phagocyte activity
|
|
US7897597B2
(en)
|
2003-08-27 |
2011-03-01 |
3M Innovative Properties Company |
Aryloxy and arylalkyleneoxy substituted imidazoquinolines
|
|
US20150071948A1
(en)
|
2003-09-26 |
2015-03-12 |
Gregory Alan Lazar |
Novel immunoglobulin variants
|
|
US8277810B2
(en)
|
2003-11-04 |
2012-10-02 |
Novartis Vaccines & Diagnostics, Inc. |
Antagonist anti-CD40 antibodies
|
|
WO2005051324A2
(en)
|
2003-11-25 |
2005-06-09 |
3M Innovative Properties Company |
Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
|
|
WO2005065678A1
(en)
|
2003-12-30 |
2005-07-21 |
3M Innovative Properties Company |
Immunomodulatory combinations
|
|
WO2005067980A2
(en)
|
2004-01-12 |
2005-07-28 |
Pointilliste, Inc. |
Design of therapeutics and therapeutics
|
|
EP1730143A2
(en)
|
2004-03-24 |
2006-12-13 |
3M Innovative Properties Company |
Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
|
|
WO2005110013A2
(en)
|
2004-04-09 |
2005-11-24 |
3M Innovative Properties Company |
Methods, compositions, and preparations for delivery of immune response modifiers
|
|
BRPI0510716A
(pt)
|
2004-05-05 |
2007-11-20 |
Merrimack Pharmaceuticals Inc |
uso de um agente de ligação bi-especìfico, agente de ligação bi-especìfico, composição de um agente de ligação bi-especìfico, e, kit
|
|
US8017779B2
(en)
|
2004-06-15 |
2011-09-13 |
3M Innovative Properties Company |
Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
|
|
EP1765348B1
(en)
|
2004-06-18 |
2016-08-03 |
3M Innovative Properties Company |
Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
|
|
BRPI0516284A
(pt)
|
2004-09-23 |
2008-09-02 |
Genentech Inc |
anticorpo construìdo com cisteìna, método de selecionar anticorpos, compostos conjugados de droga-anticorpo, composição farmacêutica, método para matar ou inibir a proliferação de células de tumor, métodos de inibir a proliferação celular e o crescimento de células de tumor, artigo manufaturado e método para produzir um composto
|
|
AU2005304771A1
(en)
|
2004-11-09 |
2006-05-18 |
University Of Southern California |
Targeted innate immunity
|
|
WO2006054310A1
(en)
|
2004-11-22 |
2006-05-26 |
Biosight Ltd. |
Activated labeling reagents and methods for preparing and using the same
|
|
EP1835935A4
(en)
|
2004-12-30 |
2009-06-17 |
Univ Rockefeller |
COMPOSITIONS AND METHODS FOR ENHANCING THE MATURATION AND FUNCTION OF DENDRITIC CELLS
|
|
AU2005322898B2
(en)
|
2004-12-30 |
2011-11-24 |
3M Innovative Properties Company |
Chiral fused (1,2)imidazo(4,5-c) ring compounds
|
|
WO2006084251A2
(en)
|
2005-02-04 |
2006-08-10 |
Coley Pharmaceutical Group, Inc. |
Aqueous gel formulations containing immune reponse modifiers
|
|
EP1845988A2
(en)
|
2005-02-11 |
2007-10-24 |
3M Innovative Properties Company |
Substituted imidazoquinolines and imidazonaphthyridines
|
|
US20100004156A1
(en)
|
2005-07-27 |
2010-01-07 |
Shalesh Kaushal |
Small Compounds That Correct Protein Misfolding and Uses Thereof
|
|
US8354249B2
(en)
|
2005-08-11 |
2013-01-15 |
Omrix Biopharmaceuticals Ltd. |
Intravenous immunoglobulin composition
|
|
ES2577514T3
(es)
|
2005-08-22 |
2016-07-15 |
The Regents Of The University Of California |
Antagonistas de TLR
|
|
AR058129A1
(es)
|
2005-10-21 |
2008-01-23 |
Genzyme Corp |
Productos terapeuticos basados en anticuerpos con actividad de adcc mejorada
|
|
EP1957099B1
(en)
|
2005-11-07 |
2015-03-25 |
The Rockefeller University |
Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
|
|
US8951528B2
(en)
|
2006-02-22 |
2015-02-10 |
3M Innovative Properties Company |
Immune response modifier conjugates
|
|
WO2007103048A2
(en)
|
2006-03-01 |
2007-09-13 |
Regents Of The University Of Colorado |
Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
|
|
MX2008013993A
(es)
|
2006-05-03 |
2009-05-11 |
Univ Colorado |
Combinación adyuvante sinergistica de anticuerpo agonista de cd40/interferona tipo 1, conjugados que la contienen y uso de los mismos como un terapeutico para aumentar la inmunidad celular.
|
|
US20080031887A1
(en)
|
2006-06-30 |
2008-02-07 |
Joseph Lustgarten |
Conjugates for inducing targeted immune responses and methods of making and using same
|
|
CN101511384A
(zh)
|
2006-06-30 |
2009-08-19 |
贝勒研究院 |
采用GM-CSF和α干扰素制成的并装载热处理的且杀死的癌细胞的树突状细胞
|
|
GB0614098D0
(en)
|
2006-07-15 |
2006-08-23 |
Mnl Pharma Ltd |
Immune response variegation with imino sugars
|
|
GB0620894D0
(en)
|
2006-10-20 |
2006-11-29 |
Univ Southampton |
Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
|
|
US20080241139A1
(en)
|
2006-10-31 |
2008-10-02 |
Regents Of The University Of Colorado |
Adjuvant combinations comprising a microbial tlr agonist, a cd40 or 4-1bb agonist, and optionally an antigen and the use thereof for inducing a synergistic enhancement in cellular immunity
|
|
US20080149123A1
(en)
|
2006-12-22 |
2008-06-26 |
Mckay William D |
Particulate material dispensing hairbrush with combination bristles
|
|
WO2008103947A2
(en)
|
2007-02-23 |
2008-08-28 |
Baylor Research Institute |
Activation of human antigen-presenting cells through clec-6
|
|
BRPI0807617A2
(pt)
|
2007-02-23 |
2014-07-22 |
Baylor Res Inst |
Aplicações terapêuticas de ativação de antígeno humano presente em células através de dectin-1.
|
|
WO2008104183A2
(en)
|
2007-03-01 |
2008-09-04 |
Symphogen A/S |
Recombinant anti-epidermal growth factor receptor antibody compositions
|
|
US8604172B2
(en)
|
2009-04-17 |
2013-12-10 |
Lpath, Inc. |
Humanized antibody compositions and methods for binding lysophosphatidic acid
|
|
EP2170931A4
(en)
|
2007-06-15 |
2010-06-30 |
Immurx Inc |
USE OF TLR AGONISTS AND / OR TYPE 1 INTERFERONS TO MITIGATE THE TOXICITY OF THERAPEUTIC REGIMES OF TNF-R AGONISTS
|
|
MX2010001194A
(es)
|
2007-07-31 |
2010-07-30 |
Univ Louisiana State |
Conjugado de polipeptido-acido nucleico para inmunoprofilaxis o inmunoterapia para desordenes neoplasicos o infecciones.
|
|
US20090155289A1
(en)
*
|
2007-11-01 |
2009-06-18 |
Steve Roberts |
Furin-cleavable peptide linkers for drug-ligand conjugates
|
|
US20100098657A1
(en)
|
2007-12-27 |
2010-04-22 |
Schafer Peter H |
Method of Treating Cancer with Immunomodulatory Compounds and IgG
|
|
CA2713137C
(en)
|
2008-01-25 |
2017-10-24 |
Hadasit Medical Research Services And Development Ltd. |
Targeting of innate immune response to tumor site
|
|
HRP20161050T1
(hr)
|
2008-04-02 |
2016-11-18 |
Macrogenics, Inc. |
Her2/neu specifična protutijela i postupci njihovog korištenja
|
|
US8236319B2
(en)
|
2008-04-30 |
2012-08-07 |
Immunogen, Inc. |
Cross-linkers and their uses
|
|
US20090325315A1
(en)
|
2008-06-30 |
2009-12-31 |
Arkray, Inc. |
Detection method of target substance, detection reagent used for the same, and the uses thereof
|
|
CN102170907A
(zh)
|
2008-08-05 |
2011-08-31 |
东丽株式会社 |
用于治疗和预防癌症的药物组合物
|
|
US20100129383A1
(en)
|
2008-10-03 |
2010-05-27 |
The Governors Of The University Of Alberta |
Bifunctional fusion molecules for the delivery of antigens to professional antigen-presenting cells
|
|
US20100150942A1
(en)
|
2008-12-03 |
2010-06-17 |
Cantor Thomas L |
Affinity purified human polyclonal antibodies and methods of making and using them
|
|
WO2010132622A2
(en)
|
2009-05-14 |
2010-11-18 |
The Regents Of The University Of California |
Anticd20-cpg conjugates and methods of treating b cell malignancies
|
|
US8524702B2
(en)
|
2009-08-18 |
2013-09-03 |
Ventirx Pharmaceuticals, Inc. |
Substituted benzoazepines as toll-like receptor modulators
|
|
US8691809B2
(en)
|
2009-08-18 |
2014-04-08 |
Ventirx Pharmaceuticals, Inc. |
Substituted benzoazepines as toll-like receptor modulators
|
|
EP2475391B1
(en)
|
2009-09-09 |
2018-09-12 |
Centrose, LLC |
Extracellular targeted drug conjugates
|
|
CA2772945A1
(en)
|
2009-09-25 |
2011-03-31 |
Xoma Technology Ltd. |
Screening methods
|
|
GB0917044D0
(en)
|
2009-09-29 |
2009-11-18 |
Cytoguide As |
Agents, uses and methods
|
|
GB0917054D0
(en)
|
2009-09-29 |
2009-11-11 |
Cytoguide As |
Agents, uses and methods
|
|
US8518405B2
(en)
|
2009-10-08 |
2013-08-27 |
The University Of North Carolina At Charlotte |
Tumor specific antibodies and uses therefor
|
|
WO2011096534A1
(ja)
|
2010-02-04 |
2011-08-11 |
東レ株式会社 |
癌の治療及び／又は予防用医薬組成物
|
|
PL2532366T3
(pl)
|
2010-02-04 |
2017-02-28 |
Toray Industries, Inc. |
Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi
|
|
CA2788545C
(en)
|
2010-02-04 |
2019-03-26 |
Toray Industries, Inc. |
Pharmaceutical composition for treating and/or preventing cancer
|
|
CA2788715C
(en)
|
2010-02-04 |
2021-06-08 |
Toray Industries, Inc. |
Pharmaceutical composition for treating and/or preventing cancer
|
|
CA2788547C
(en)
|
2010-02-04 |
2018-06-05 |
Toray Industries, Inc. |
Pharmaceutical composition for treating and/or preventing cancer
|
|
US9203872B2
(en)
|
2010-02-19 |
2015-12-01 |
Microsoft Technology Licensing, Llc |
Distributed connectivity policy enforcement with ICE
|
|
GB201003293D0
(en)
|
2010-02-26 |
2010-04-14 |
Adjuvantix Ltd |
Cancer vaccine
|
|
WO2011109789A2
(en)
|
2010-03-05 |
2011-09-09 |
The Johns Hopkins University |
Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
|
|
CN103154034B
(zh)
|
2010-04-13 |
2016-06-08 |
塞尔德克斯医疗公司 |
结合人cd27的抗体及其用途
|
|
US20120213771A1
(en)
|
2010-04-13 |
2012-08-23 |
Celldex Therapeutics Inc. |
Antibodies that bind human cd27 and uses thereof
|
|
EP2566518A4
(en)
|
2010-05-07 |
2013-12-25 |
Baylor Res Inst |
CROSS-LINKED MEDICATION WITH DENDRITIC CELL IMMUNORE-RECEPTORS (DCIR) OF HUMAN CD8 + T CELLS
|
|
AU2011252883B2
(en)
|
2010-05-14 |
2015-09-10 |
Abbvie Inc. |
IL-1 binding proteins
|
|
AU2011265054B2
(en)
|
2010-06-08 |
2016-09-15 |
Genentech, Inc. |
Cysteine engineered antibodies and conjugates
|
|
EP2594589A1
(en)
|
2010-06-10 |
2013-05-22 |
Sapporo Medical University |
ANTI-Trop-2 ANTIBODY
|
|
HRP20191305T1
(hr)
|
2010-07-09 |
2019-10-18 |
Bioverativ Therapeutics Inc. |
Preradive jednolančane molekule i polipeptidi izrađeni koristeći iste
|
|
KR20130050966A
(ko)
|
2010-07-12 |
2013-05-16 |
씨오브이엑스 테크놀로지스 아일랜드 리미티드 |
다기능적 항체 접합체
|
|
WO2012021834A1
(en)
|
2010-08-13 |
2012-02-16 |
Baylor Research Institute |
Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
|
|
RU2603467C2
(ru)
|
2010-10-01 |
2016-11-27 |
Вентиркс Фармасьютикалз, Инк. |
Терапевтическое применение агониста tlr и комбинированная терапия
|
|
US20120328605A1
(en)
|
2010-10-27 |
2012-12-27 |
Daniel Larocque |
Compositions and uses
|
|
EP2638066A4
(en)
|
2010-11-09 |
2015-06-03 |
Medimmune Llc |
ANTIBODY EQUIPMENT FOR HOMOGENEOUS CONJUGATION
|
|
US20120171229A1
(en)
|
2010-12-30 |
2012-07-05 |
Selecta Biosciences, Inc. |
Synthetic nanocarriers with reactive groups that release biologically active agents
|
|
AR085633A1
(es)
|
2011-03-08 |
2013-10-16 |
Baylor Res Inst |
Coadyuvantes basados en anticuerpos que son dirigidos directamente a las celulas presentadoras en antigenos
|
|
CA2831294A1
(en)
|
2011-03-25 |
2012-10-04 |
Baylor Research Institute |
Compositions and methods to immunize against hepatitis c virus
|
|
MX338353B
(es)
|
2011-04-20 |
2016-04-13 |
Medimmune Llc |
Anticuerpos y otras moleculas que se unen a b7 - h1 y pd - 1.
|
|
US8728486B2
(en)
|
2011-05-18 |
2014-05-20 |
University Of Kansas |
Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds
|
|
US20140088021A1
(en)
|
2011-05-27 |
2014-03-27 |
Nektar Therapeutics |
Water-Soluble Polymer-Linked Binding Moiety and Drug Compounds
|
|
MX355623B
(es)
|
2011-06-03 |
2018-04-25 |
3M Innovative Properties Co |
Hidrazino-1h-imidazoquinolin-4-aminas y conjugados elaborados a partir de las mismas.
|
|
MX347240B
(es)
|
2011-06-03 |
2017-04-20 |
3M Innovative Properties Co |
Ligadores heterobifuncionales con segmentos polietilenglicol y conjugados modificadores de la respuesta inmunitaria elaborados a partir de los mismos.
|
|
WO2012170072A1
(en)
|
2011-06-06 |
2012-12-13 |
Immungene, Inc. |
Engineered antibody-tnfsf member ligand fusion molecules
|
|
HUE033149T2
(en)
|
2011-08-04 |
2017-11-28 |
Toray Industries |
A pharmaceutical composition for the treatment and / or prevention of cancer
|
|
AU2012290949B2
(en)
|
2011-08-04 |
2017-03-02 |
Toray Industries, Inc. |
Pharmaceutical composition for treatment and/or prevention of pancreatic cancer
|
|
PL2740795T3
(pl)
|
2011-08-04 |
2017-04-28 |
Toray Industries, Inc. |
Kompozycja lekowa do leczenia nowotworu i/lub zapobiegania nowotworowi
|
|
KR101984554B1
(ko)
|
2011-08-04 |
2019-05-31 |
도레이 카부시키가이샤 |
췌장암의 검출 방법
|
|
PL2740794T3
(pl)
|
2011-08-04 |
2018-09-28 |
Toray Industries, Inc. |
Kompozycja farmaceutyczna do leczenia i/lub profilaktyki nowotworów
|
|
KR101968498B1
(ko)
|
2011-08-04 |
2019-04-12 |
도레이 카부시키가이샤 |
암의 치료 및/또는 예방용 의약 조성물
|
|
CA2844030C
(en)
|
2011-08-04 |
2019-09-03 |
Toray Industries, Inc. |
Pharmaceutical composition for treatment and/or prophylaxis of cancer
|
|
GB201113570D0
(en)
|
2011-08-05 |
2011-09-21 |
Glaxosmithkline Biolog Sa |
Vaccine
|
|
JP6120848B2
(ja)
|
2011-08-15 |
2017-04-26 |
メディミューン，エルエルシー |
抗ｂ７−ｈ４抗体およびその使用
|
|
US20140363461A1
(en)
|
2011-09-01 |
2014-12-11 |
Fabio Bagnoli |
Adjuvanted formulations of staphylococcus aureus antigens
|
|
US9308253B2
(en)
|
2011-09-19 |
2016-04-12 |
The Johns Hopkins University |
Cancer immunotherapy
|
|
NL2007536C2
(en)
|
2011-10-05 |
2013-04-08 |
Academisch Ziekenhuis Leiden Lumc |
Adjuvant compound.
|
|
US20130108619A1
(en)
|
2011-11-02 |
2013-05-02 |
Isaac Melamed |
Intravenous immunoglobulin processing, diagnostic, and treatment systems and methods
|
|
EP2776070A4
(en)
|
2011-11-09 |
2016-02-10 |
Ascend Biopharmaceuticals Ltd |
IMMUNOMODULATORY CONJUGATES
|
|
SG11201401699WA
(en)
|
2011-11-11 |
2014-09-26 |
Rinat Neuroscience Corp |
Antibodies specific for trop-2 and their uses
|
|
WO2013093809A1
(en)
|
2011-12-23 |
2013-06-27 |
Pfizer Inc. |
Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
|
|
EP3447071A1
(en)
|
2012-01-09 |
2019-02-27 |
Pfizer Healthcare Ireland |
Mutant antibodies and conjugation thereof
|
|
PT2802606T
(pt)
|
2012-01-10 |
2018-07-13 |
Biogen Ma Inc |
Melhoramento do transporte de moléculas terapêuticas através da barreira hematoencefálica
|
|
US20130177574A1
(en)
|
2012-01-11 |
2013-07-11 |
Paul I. Terasaki Foundation Laboratory |
ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE
|
|
MX2014009289A
(es)
|
2012-02-01 |
2015-09-08 |
Compugen Ltd |
Anticuerpos c1orf32 y usos de los mismos para el tratamiento del cancer.
|
|
EP2824114B1
(en)
|
2012-02-21 |
2019-05-22 |
Toray Industries, Inc. |
Pharmaceutical composition for treatment of cancer
|
|
EP2818481B1
(en)
|
2012-02-21 |
2019-08-07 |
Toray Industries, Inc. |
Pharmaceutical composition for treatment and/or prevention of cancer
|
|
ES2739612T3
(es)
|
2012-02-21 |
2020-02-03 |
Toray Industries |
Composición farmacéutica para el tratamiento de cáncer
|
|
ES2643241T3
(es)
|
2012-02-21 |
2017-11-21 |
Toray Industries, Inc. |
Composición medicinal para tratar y/o prevenir el cáncer
|
|
MX366864B
(es)
|
2012-02-27 |
2019-07-26 |
Amunix Operating Inc |
Composiciones de conjugados de xten y métodos para realizarlas.
|
|
PL2832365T3
(pl)
|
2012-03-30 |
2018-04-30 |
Toray Industries, Inc. |
Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi wątroby
|
|
US9428581B2
(en)
|
2012-03-30 |
2016-08-30 |
Toray Industries, Inc. |
Pharmaceutical composition for treatment and/or prevention of gallbladder cancer
|
|
AU2013245645A1
(en)
|
2012-04-13 |
2014-11-13 |
Whitehead Institute For Biomedical Research |
Sortase- modified VHH domains and uses thereof
|
|
WO2013166110A1
(en)
|
2012-05-02 |
2013-11-07 |
Yale University |
Tlr-agonist-conjugated antibody recruiting molecules (tlr_arms)
|
|
WO2013180811A1
(en)
|
2012-05-30 |
2013-12-05 |
Life Technologies Corporation |
FLUOROGENIC pH-SENSITIVE DYES AND THEIR METHODS OF USE
|
|
EP2674170B1
(en)
|
2012-06-15 |
2014-11-19 |
Invivogen |
Novel compositions of TLR7 and/or TLR8 agonists conjugated to lipids
|
|
UA114108C2
(uk)
|
2012-07-10 |
2017-04-25 |
Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем |
Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання
|
|
CN103566377A
(zh)
|
2012-07-18 |
2014-02-12 |
上海博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
|
US9382329B2
(en)
|
2012-08-14 |
2016-07-05 |
Ibc Pharmaceuticals, Inc. |
Disease therapy by inducing immune response to Trop-2 expressing cells
|
|
US20140065096A1
(en)
|
2012-09-05 |
2014-03-06 |
Regen BioPharma, Inc. |
Cancer therapy by ex vivo activated autologous immune cells
|
|
KR102626525B1
(ko)
|
2013-02-08 |
2024-01-19 |
노파르티스 아게 |
면역접합체의 제조를 위한 항체의 변형에 사용되는 특정 부위
|
|
EP2787005A1
(en)
|
2013-04-02 |
2014-10-08 |
Activartis Biotech GmbH |
Targeted cancer immune therapy
|
|
AR095882A1
(es)
|
2013-04-22 |
2015-11-18 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
|
|
US20180104349A9
(en)
|
2013-04-28 |
2018-04-19 |
Gang Qin |
Novel linker, preparation method, and application thereof
|
|
WO2015172800A1
(en)
|
2014-05-12 |
2015-11-19 |
Numab Ag |
Novel multispecific molecules and novel treatment methods based on such multispecific molecules
|
|
WO2015014376A1
(en)
|
2013-07-31 |
2015-02-05 |
Biontech Ag |
Diagnosis and therapy of cancer involving cancer stem cells
|
|
RU2678138C2
(ru)
|
2013-08-09 |
2019-01-23 |
Торэй Индастриз, Инк. |
Фармацевтическая композиция для лечения и/или профилактики рака
|
|
AU2014337317A1
(en)
|
2013-10-15 |
2016-09-15 |
Sorrento Therapeutics Inc. |
Drug-conjugates with a targeting molecule and two different drugs
|
|
GB201321242D0
(en)
|
2013-12-02 |
2014-01-15 |
Immune Targeting Systems Its Ltd |
Immunogenic compound
|
|
US20150190506A1
(en)
|
2013-12-17 |
2015-07-09 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
|
EP3647324A1
(en)
|
2013-12-17 |
2020-05-06 |
F. Hoffmann-La Roche AG |
Methods of treating cancers using pd-1 axis binding antagonists and taxanes
|
|
HRP20190056T1
(hr)
|
2013-12-25 |
2019-02-22 |
Daiichi Sankyo Company, Limited |
Konjugat anti-trop2 antitijelo-lijek
|
|
CN104861067A
(zh)
*
|
2014-01-10 |
2015-08-26 |
博笛生物科技有限公司 |
用于免疫疗法的化合物和组合物
|
|
CN104861063A
(zh)
*
|
2014-01-10 |
2015-08-26 |
博笛生物科技有限公司 |
靶向her2阳性肿瘤的化合物和组合物
|
|
CN105899537A
(zh)
|
2014-01-10 |
2016-08-24 |
博笛生物科技（北京）有限公司 |
靶向表达egfr的肿瘤的化合物和组合物
|
|
EP3096787A4
(en)
|
2014-01-22 |
2018-02-07 |
The Board of Trustees of the Leland Stanford Junior University |
Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy
|
|
LT3107563T
(lt)
|
2014-02-21 |
2021-07-12 |
Ecole Polytechnique Fédérale De Lausanne (Epfl) Epfl-Tto |
Gliko-nukreipiantys terapiniai agenai
|
|
JP6357327B2
(ja)
|
2014-03-11 |
2018-07-11 |
株式会社クレハ |
フッ化ビニリデン系共重合体、その製造方法、ゲル電解質および非水系電池
|
|
EP3129407A2
(en)
|
2014-03-12 |
2017-02-15 |
Novartis Ag |
Specific sites for modifying antibodies to make immunoconjugates
|
|
ES2940903T3
(es)
|
2014-03-19 |
2023-05-12 |
Genzyme Corp |
Glucomanipulación específica del sitio de restos orientadores
|
|
ES2719584T3
(es)
|
2014-04-11 |
2019-07-11 |
Medimmune Llc |
Compuestos conjugados que comprenden anticuerpos modificados por ingeniería genética con cisteína
|
|
AR100137A1
(es)
|
2014-04-22 |
2016-09-14 |
Hoffmann La Roche |
Compuestos 4-amino-imidazoquinolina
|
|
WO2015165413A1
(zh)
|
2014-04-29 |
2015-11-05 |
秦刚 |
一种新型的稳定型抗体药物耦联物及其制备方法和用途
|
|
EP3145552B1
(en)
|
2014-05-23 |
2020-03-04 |
Novartis AG |
Methods for making conjugates from disulfide-containing proteins
|
|
WO2015187637A1
(en)
|
2014-06-02 |
2015-12-10 |
Baylor Research Institute |
Methods and compositions for treating allergy and inflammatory diseases
|
|
ES2901705T3
(es)
|
2014-06-06 |
2022-03-23 |
Bristol Myers Squibb Co |
Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (GITR) y usos de los mismos
|
|
EP4001311B1
(en)
|
2014-07-09 |
2025-11-05 |
Birdie Biopharmaceuticals Inc. |
Anti-pd-l1/pd-1 combinations for treating tumors
|
|
CN112546230A
(zh)
|
2014-07-09 |
2021-03-26 |
博笛生物科技有限公司 |
用于治疗癌症的联合治疗组合物和联合治疗方法
|
|
WO2016011401A1
(en)
|
2014-07-18 |
2016-01-21 |
Kedl Ross M |
Immunostimulatory combinations and use thereof
|
|
AU2015292406B2
(en)
|
2014-07-25 |
2021-03-11 |
Cytomx Therapeutics, Inc |
Anti-CD3 antibodies, activatable anti-CD3 antibodies, multispecific anti-CD3 antibodies, multispecific activatable anti-CD3 antibodies, and methods of using the same
|
|
WO2016028149A1
(en)
|
2014-08-20 |
2016-02-25 |
Tu Eindhoven |
Ureidopyrimidone supramolecular complexes for compound delivery into cells
|
|
JP2017526673A
(ja)
*
|
2014-08-27 |
2017-09-14 |
国立大学法人九州大学 |
アジュバント
|
|
CN112546238A
(zh)
|
2014-09-01 |
2021-03-26 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-pd-l1结合物
|
|
US9884866B2
(en)
|
2014-09-08 |
2018-02-06 |
Regents Of The University Of Minnesota |
Immunomodulators and immunomodulator conjugates
|
|
JP2017535528A
(ja)
|
2014-10-03 |
2017-11-30 |
ノバルティス アーゲー |
組み合わせ治療
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
US20170304433A1
(en)
|
2014-10-09 |
2017-10-26 |
Wake Forest University Health Sciences |
Vaccine compositions and methods of use to treat neonatal subjects
|
|
GB201418004D0
(en)
|
2014-10-10 |
2014-11-26 |
Isis Innovation |
Polymer adjuvant
|
|
US9988452B2
(en)
|
2014-10-14 |
2018-06-05 |
Novartis Ag |
Antibody molecules to PD-L1 and uses thereof
|
|
EP3209334A2
(en)
|
2014-10-20 |
2017-08-30 |
Igenica Biotherapeutics, Inc. |
Novel antibody-drug conjugates and related compounds, compositions, and methods of use
|
|
WO2016064899A1
(en)
|
2014-10-21 |
2016-04-28 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy
|
|
SI3221363T1
(sl)
|
2014-11-21 |
2020-09-30 |
Bristol-Myers Squibb Company |
Protitelesa proti CD73 in njihova uporaba
|
|
CA2968837A1
(en)
|
2014-11-25 |
2016-06-02 |
Endocyte, Inc. |
Methods of treating cancer by targeting tumor-associated macrophages
|
|
EP3233918A1
(en)
|
2014-12-19 |
2017-10-25 |
Novartis AG |
Combination therapies
|
|
RS61470B1
(sr)
|
2014-12-31 |
2021-03-31 |
Checkmate Pharmaceuticals Inc |
Kombinovana antitumorska imunoterapija
|
|
JP6676058B2
(ja)
|
2015-01-14 |
2020-04-08 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
ヘテロアリーレン架橋したベンゾジアゼピン二量体、そのコンジュゲート、ならびに製造および使用方法
|
|
TWI632160B
(zh)
|
2015-01-16 |
2018-08-11 |
中央研究院 |
具有標的部分及效應部分的分子構建體
|
|
ES2761861T3
(es)
|
2015-01-21 |
2020-05-21 |
Univ Leland Stanford Junior |
Uso de agonistas de TLR y agente anti-CD47 para mejorar la fagocitosis de las células cancerosas
|
|
US20180044429A1
(en)
|
2015-03-09 |
2018-02-15 |
Celldex Therapeutics, Inc. |
Cd27 agonists
|
|
TWI703141B
(zh)
|
2015-03-12 |
2020-09-01 |
大陸商廣東東陽光藥業有限公司 |
作為丙型肝炎抑制劑的化合物及其在藥物中的應用
|
|
SG11201707383PA
(en)
|
2015-03-13 |
2017-10-30 |
Cytomx Therapeutics Inc |
Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
|
|
KR102749339B1
(ko)
|
2015-03-23 |
2025-01-03 |
바이엘 파마 악티엔게젤샤프트 |
항-ceacam6 항체 및 그의 용도
|
|
US20180117171A1
(en)
|
2015-04-01 |
2018-05-03 |
President And Fellows Of Harvard College |
Immunoconjugates for programming or reprogramming of cells
|
|
EP3286224A4
(en)
|
2015-04-22 |
2018-11-14 |
Immunomedics, Inc. |
Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
|
|
MX388350B
(es)
|
2015-05-04 |
2025-03-19 |
Cytomx Therapeutics Inc |
Anticuerpos anti-cd166, anticuerpos anti-cd166 activables, y metodos de uso de los mismos.
|
|
EP3292151A1
(en)
|
2015-05-04 |
2018-03-14 |
Cytomx Therapeutics Inc. |
Anti-itga3 antibodies, activatable anti-itga3 antibodies, and methods of use thereof
|
|
US10179817B2
(en)
|
2015-05-04 |
2019-01-15 |
Cytomx Therapeutics, Inc. |
Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereof
|
|
US20160324981A1
(en)
|
2015-05-08 |
2016-11-10 |
The California Institute For Biomedical Research |
Liver x receptor agonists and uses thereof
|
|
US10314854B2
(en)
|
2015-05-15 |
2019-06-11 |
University Of Iowa Foundation |
Methods for treating tumors in situ including intratumor injection of cytotoxic particles and immune checkpoint blockade therapy
|
|
TWI614030B
(zh)
|
2015-05-20 |
2018-02-11 |
免疫功坊股份有限公司 |
具有標的部分及效應部分的分子構建體
|
|
EP3298145A4
(en)
|
2015-05-22 |
2018-12-12 |
La Trobe University |
Method of diagnosis of breast cancer
|
|
KR20250151554A
(ko)
|
2015-05-29 |
2025-10-21 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|
|
SG10202008304TA
(en)
|
2015-05-29 |
2020-10-29 |
Bristol Myers Squibb Co |
Antibodies against ox40 and uses thereof
|
|
US20180267024A1
(en)
|
2015-06-08 |
2018-09-20 |
Lophius Biosciences Gmbh |
Composition for determination of cell-mediated immune responsiveness
|
|
CN108026123B
(zh)
|
2015-06-15 |
2021-02-05 |
杭州多禧生物科技有限公司 |
用于偶联的亲水链接体
|
|
WO2016205551A2
(en)
|
2015-06-16 |
2016-12-22 |
The Regents Of The University Of California |
Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function
|
|
WO2016205566A1
(en)
|
2015-06-16 |
2016-12-22 |
The Regents Of The University Of California |
Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function
|
|
US10975112B2
(en)
|
2015-06-16 |
2021-04-13 |
Hangzhou Dac Biotech Co., Ltd. |
Linkers for conjugation of cell-binding molecules
|
|
WO2016203025A1
(en)
|
2015-06-17 |
2016-12-22 |
Curevac Ag |
Vaccine composition
|
|
GB201511546D0
(en)
|
2015-07-01 |
2015-08-12 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
|
|
EP3317246A4
(en)
|
2015-07-04 |
2019-02-27 |
Suzhou M-conj Biotech Co., Ltd. |
SPECIFIC CONJUGATION OF A CELL BINDING MOLECULE
|
|
CN113350518A
(zh)
|
2015-07-12 |
2021-09-07 |
杭州多禧生物科技有限公司 |
与细胞结合分子的共轭偶联的桥连接体
|
|
CN114591433A
(zh)
|
2015-07-13 |
2022-06-07 |
西托姆克斯治疗公司 |
抗pd-1抗体、可活化抗pd-1抗体及其使用方法
|
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
|
EP3878465A1
(en)
|
2015-07-29 |
2021-09-15 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
|
CN108025051B
(zh)
|
2015-07-29 |
2021-12-24 |
诺华股份有限公司 |
包含抗pd-1抗体分子的联合疗法
|
|
WO2017019894A1
(en)
|
2015-07-29 |
2017-02-02 |
Novartis Ag |
Combination therapies comprising antibody molecules to lag-3
|
|
AU2016303497A1
(en)
|
2015-07-31 |
2018-03-01 |
Tarveda Therapeutics, Inc. |
Compositions and methods for immuno-oncology therapies
|
|
WO2017024296A1
(en)
|
2015-08-06 |
2017-02-09 |
Memorial Sloan Kettering Cancer Center |
Methods and compositions for tumor therapy
|
|
TW201716084A
(zh)
|
2015-08-06 |
2017-05-16 |
葛蘭素史克智慧財產發展有限公司 |
組合物及其用途與治療
|
|
CN115300640A
(zh)
|
2015-08-10 |
2022-11-08 |
杭州多禧生物科技有限公司 |
新型连接体及其用于药物和生物分子的特异性偶联
|
|
CN107922416B
(zh)
|
2015-08-31 |
2021-07-02 |
3M创新有限公司 |
含有取代的胍基团的咪唑并[4,5-c]环化合物
|
|
WO2017040233A1
(en)
|
2015-08-31 |
2017-03-09 |
3M Innovative Properties Company |
GUANIDINE SUBSTITUTED IMIDAZO[4,5-c] RING COMPOUNDS
|
|
WO2017036255A1
(en)
|
2015-09-01 |
2017-03-09 |
Tse-Wen Chang |
Molecular constructs for preventing the formation of blood clot and/or treating thrombosis
|
|
US10799580B2
(en)
|
2015-09-09 |
2020-10-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Expression vector delivery system and use thereof for inducing an immune response
|
|
RU2722149C1
(ru)
|
2015-09-14 |
2020-05-27 |
Пфайзер Инк. |
Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2
|
|
US20180273948A1
(en)
|
2015-09-25 |
2018-09-27 |
Tarveda Therapeutics, Inc. |
RNAi CONJUGATES, PARTICLES AND FORMULATIONS THEREOF
|
|
EP3356371A4
(en)
|
2015-09-29 |
2020-06-24 |
The University of Chicago |
POLYMER CONJUGATE VACCINES
|
|
MA44334A
(fr)
|
2015-10-29 |
2018-09-05 |
Novartis Ag |
Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
|
|
EP3370726A4
(en)
|
2015-11-02 |
2019-06-12 |
VentiRx Pharmaceuticals, Inc. |
USE OF TLR8 AGONISTS FOR CANCER TREATMENT
|
|
WO2017083525A1
(en)
|
2015-11-11 |
2017-05-18 |
Opi Vi- Ip Holdco Llc |
Composition and methods for anti-tnfr2 antibodies
|
|
WO2017087280A1
(en)
|
2015-11-16 |
2017-05-26 |
Genentech, Inc. |
Methods of treating her2-positive cancer
|
|
TWI637966B
(zh)
|
2015-11-30 |
2018-10-11 |
輝瑞股份有限公司 |
用於部位專一性接合之抗體和抗體片段
|
|
KR101795388B1
(ko)
|
2015-12-02 |
2017-11-09 |
현대자동차 주식회사 |
차량용 자동변속기의 유성기어트레인
|
|
US20170158772A1
(en)
|
2015-12-07 |
2017-06-08 |
Opi Vi - Ip Holdco Llc |
Compositions of antibody construct - agonist conjugates and methods of use thereof
|
|
CA3007311A1
(en)
|
2015-12-07 |
2017-06-15 |
Opi Vi - Ip Holdco Llc |
Compositions of antibody construct-agonist conjugates and methods of use thereof
|
|
CA3007671A1
(en)
|
2015-12-17 |
2017-06-22 |
Novartis Ag |
Antibody molecules to pd-1 and uses thereof
|
|
WO2017117269A1
(en)
|
2015-12-29 |
2017-07-06 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for dectin-2 stimulation and cancer immunotherapy
|
|
CN115350279A
(zh)
|
2016-01-07 |
2022-11-18 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-her2组合
|
|
CN106943596A
(zh)
|
2016-01-07 |
2017-07-14 |
博笛生物科技（北京）有限公司 |
用于治疗肿瘤的抗-cd20组合
|
|
CN106943597A
(zh)
|
2016-01-07 |
2017-07-14 |
博笛生物科技（北京）有限公司 |
用于治疗肿瘤的抗-egfr组合
|
|
MY195114A
(en)
|
2016-02-04 |
2023-01-10 |
Robert Yongxin Zhao |
Specific Conjugation Linkers, Specific Immunoconjugates Thereof, Methods of Making and uses Such Conjugates Thereof
|
|
AU2017238172B2
(en)
|
2016-03-21 |
2024-06-27 |
Marengo Therapeutics, Inc. |
Multispecific and multifunctional molecules and uses thereof
|
|
EP3442592A4
(en)
|
2016-04-13 |
2019-11-27 |
Tarveda Therapeutics, Inc. |
NEUROTENSIN RECEPTOR BINDING CONJUGATES AND FORMULATIONS THEREOF
|
|
SG11201808821WA
(en)
|
2016-04-18 |
2018-11-29 |
Celldex Therapeutics Inc |
Agonistic antibodies that bind human cd40 and uses thereof
|
|
WO2017184735A1
(en)
|
2016-04-19 |
2017-10-26 |
Ifm Therapeutics, Inc |
Nlrp3 modulators
|
|
CN109071535B
(zh)
|
2016-04-19 |
2021-10-08 |
先天肿瘤免疫公司 |
Nlrp3调节剂
|
|
IL262295B2
(en)
|
2016-05-09 |
2023-09-01 |
Igm Biosciences Inc |
Antibodies against pd–l1
|
|
TW201801751A
(zh)
|
2016-05-13 |
2018-01-16 |
塔維達治療公司 |
靶向構建體及其製劑
|
|
WO2017210246A2
(en)
|
2016-05-31 |
2017-12-07 |
Tarveda Therapeutics, Inc. |
Penicillamine conjugates and particles and formulations thereof
|
|
WO2017223085A2
(en)
|
2016-06-20 |
2017-12-28 |
The Regents Of The University Of Michigan |
Compositions and methods for delivery of biomacromolecule agents
|
|
US10858483B2
(en)
|
2016-07-06 |
2020-12-08 |
University Of Maryland, College Park |
Polyphosphazene polyelectrolytes and uses thereof
|
|
AU2017292934B9
(en)
*
|
2016-07-07 |
2024-08-29 |
Bolt Biotherapeutics, Inc. |
Antibody adjuvant conjugates
|
|
KR102497742B1
(ko)
|
2016-08-30 |
2023-02-10 |
다나-파버 캔서 인스티튜트 인크. |
약물 전달 조성물 및 그의 용도
|
|
WO2018045150A1
(en)
|
2016-09-02 |
2018-03-08 |
Gilead Sciences, Inc. |
4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
|
|
US11274115B2
(en)
|
2016-09-07 |
2022-03-15 |
Glaxosmithkline Biological Sa |
Imidazoquinoline derivatives and their use in therapy
|
|
US10954233B2
(en)
|
2016-09-09 |
2021-03-23 |
Novartis Ag |
Compounds and compositions as inhibitors of endosomal toll-like receptors
|
|
EP3532505A4
(en)
|
2016-10-25 |
2019-12-25 |
Urogen Pharma Ltd. |
BODY CAVES IMMUNODULATING TREATMENTS
|
|
WO2018079740A1
(ja)
|
2016-10-28 |
2018-05-03 |
東レ株式会社 |
癌の治療及び／又は予防用医薬組成物
|
|
CN116143678A
(zh)
|
2016-11-14 |
2023-05-23 |
杭州多禧生物科技有限公司 |
偶联连接体，含有此连接体的细胞结合分子-药物偶联物及其制备和应用
|
|
WO2018112108A1
(en)
|
2016-12-13 |
2018-06-21 |
Bolt Biotherapeutics, Inc. |
Antibody adjuvant conjugates
|
|
EP3555330A4
(en)
|
2016-12-15 |
2020-05-13 |
Arconic Technologies LLC |
CORROSION RESISTANT ALUMINUM ALLOY
|
|
JP7128529B2
(ja)
|
2016-12-23 |
2022-08-31 |
アールイーエムディー バイオセラピューティクス，インコーポレイテッド |
プログラム死リガンド－１（ｐｄ－ｌ１）に結合する抗体を使用する免疫
|
|
RU2768404C2
(ru)
|
2016-12-23 |
2022-03-24 |
Ремд Биотерапьютикс, Инк. |
Иммунотерапия с применением антител, связывающих белок 1 программируемой смерти клеток (pd-1)
|
|
KR102619747B1
(ko)
|
2017-01-10 |
2023-12-29 |
넥타르 테라퓨틱스 |
Tlr 효현제 화합물의 다중-아암 중합체 컨쥬게이트 및 관련 면역 요법적 치료 방법
|
|
US20190336615A1
(en)
|
2017-01-27 |
2019-11-07 |
Silverback Therapeutics, Inc. |
Tumor targeting conjugates and methods of use thereof
|
|
EP3576782A4
(en)
|
2017-02-02 |
2020-12-30 |
Silverback Therapeutics, Inc. |
COMPOSITIONS OF RECOMBINATION PRODUCT-PEPTIDE AND THEIR METHODS OF USE
|
|
TWI674261B
(zh)
|
2017-02-17 |
2019-10-11 |
美商英能腫瘤免疫股份有限公司 |
Nlrp3 調節劑
|
|
WO2018156617A2
(en)
|
2017-02-22 |
2018-08-30 |
The Regents Of The University Of Michigan |
Compositions and methods for delivery of polymer / biomacromolecule conjugates
|
|
WO2018162446A1
(en)
|
2017-03-06 |
2018-09-13 |
Merck Patent Gmbh |
Aqueous anti-pd-l1 antibody formulation
|
|
EP3595668B1
(en)
|
2017-03-15 |
2021-07-21 |
Silverback Therapeutics, Inc. |
Benzazepine compounds, conjugates, and uses thereof
|
|
AU2018233403B2
(en)
|
2017-03-16 |
2021-02-25 |
Immunwork Inc. |
Linker units and molecular constructs comprising same
|
|
US11464854B2
(en)
|
2017-03-23 |
2022-10-11 |
Children's Medical Center Corporation |
Methods and compositions relating to adjuvants
|
|
CA3056816A1
(en)
|
2017-03-31 |
2018-10-04 |
Zymeworks Inc. |
Tumor antigen presentation inducer constructs and uses thereof
|
|
JP2020515629A
(ja)
|
2017-04-04 |
2020-05-28 |
アヴィディア テクノロジーズ， インコーポレイテッド |
免疫応答を誘導するためのペプチドベースのワクチン、それらの製造方法および使用
|
|
MX2019011957A
(es)
|
2017-04-06 |
2019-11-07 |
Hangzhou Dac Biotech Co Ltd |
Conjugacion de un farmaco citotoxico con enlace bis.
|
|
US20180296685A1
(en)
|
2017-04-13 |
2018-10-18 |
Tarveda Therapeutics, Inc. |
Targeted constructs and formulations thereof
|
|
PT3609540T
(pt)
|
2017-04-14 |
2023-03-01 |
Bolt Biotherapeutics Inc |
Método de síntese de imunoconjugado
|
|
CA3058944A1
(en)
|
2017-04-19 |
2018-10-25 |
Elstar Therapeutics, Inc. |
Multispecific molecules and uses thereof
|
|
CN108794467A
(zh)
|
2017-04-27 |
2018-11-13 |
博笛生物科技有限公司 |
2-氨基-喹啉衍生物
|
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
|
AR111760A1
(es)
|
2017-05-19 |
2019-08-14 |
Novartis Ag |
Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
|
|
EP4509132A3
(en)
|
2017-05-26 |
2025-11-19 |
The Johns Hopkins University |
Multifunctional antibody-ligand traps to modulate immune tolerence
|
|
EP3634401A1
(en)
|
2017-06-07 |
2020-04-15 |
Silverback Therapeutics, Inc. |
Antibody construct conjugates
|
|
AU2018279105A1
(en)
|
2017-06-07 |
2019-12-19 |
Silverback Therapeutics, Inc. |
Antibody conjugates of immune-modulatory compounds and uses thereof
|
|
CA3067268A1
(en)
|
2017-06-23 |
2018-12-27 |
Birdie Biopharmaceuticals, Inc. |
Crystalline resiquimod monosulfate anhydrate and its preparation and uses
|
|
AU2018290880A1
(en)
|
2017-06-28 |
2020-01-16 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for Dectin-2 stimulation and cancer immunotherapy
|
|
WO2019023622A1
(en)
|
2017-07-27 |
2019-01-31 |
The Board Of Trustees Of The Leland Stanford Junior University |
POLYMERIC NANOPARTICLES FOR IMPROVED ANTICANCERIC IMMUNOTHERAPY
|
|
US10472361B2
(en)
|
2017-08-16 |
2019-11-12 |
Bristol-Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
|
|
US10457681B2
(en)
|
2017-08-16 |
2019-10-29 |
Bristol_Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor
|
|
US10487084B2
(en)
|
2017-08-16 |
2019-11-26 |
Bristol-Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
|
|
US10494370B2
(en)
|
2017-08-16 |
2019-12-03 |
Bristol-Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
|
|
US10508115B2
(en)
|
2017-08-16 |
2019-12-17 |
Bristol-Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
|
|
EP3668548A2
(en)
|
2017-08-17 |
2020-06-24 |
Nektar Therapeutics |
Immunotherapeutic tumor treatment method
|
|
US11713356B2
(en)
|
2017-10-13 |
2023-08-01 |
Ose Immunotherapeutics |
Modified bifunctional anti-human signal regulatory protein alpha (SIRPa) antibody and method of use thereof for treating cancer
|
|
WO2019084060A1
(en)
|
2017-10-24 |
2019-05-02 |
Silverback Therapeutics, Inc. |
CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS
|
|
WO2019099412A1
(en)
|
2017-11-14 |
2019-05-23 |
Dynavax Technologies Corporation |
Cleavable conjugates of tlr7/8 agonist compounds, methods for preparation, and uses thereof
|
|
WO2019118884A1
(en)
|
2017-12-15 |
2019-06-20 |
Silverback Therapeutics, Inc. |
Antibody construct-drug conjugate for the treatment of hepatitis
|
|
CA3086040A1
(en)
|
2017-12-19 |
2019-06-27 |
Blaze Bioscience, Inc. |
Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof
|
|
KR20210006338A
(ko)
|
2018-03-13 |
2021-01-18 |
오제 이뮈노테라프틱스 |
항-인간 SIRPa v1 항체의 이용 및 항-SIRPa v1 항체를 생산하는 방법
|
|
US20210009711A1
(en)
|
2018-03-14 |
2021-01-14 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
|
WO2019195278A1
(en)
|
2018-04-02 |
2019-10-10 |
Silverback Therapeutics, Inc. |
Alk5 inhibitors, conjugates, and uses thereof
|
|
CN108379591B
(zh)
|
2018-04-03 |
2022-03-29 |
深圳大学 |
免疫激动剂靶向化合物的合成及其应用
|
|
WO2019209811A1
(en)
|
2018-04-24 |
2019-10-31 |
Bristol-Myers Squibb Company |
Macrocyclic toll-like receptor 7 (tlr7) agonists
|
|
WO2019222676A1
(en)
|
2018-05-17 |
2019-11-21 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates
|
|
IL311536A
(en)
|
2018-06-04 |
2024-05-01 |
Tufts College |
Binder-drug conjugates activated in the microenvironment and their related uses
|
|
CN114014932A
(zh)
|
2018-07-09 |
2022-02-08 |
启德医药科技（苏州）有限公司 |
滋养层细胞表面抗原2(trop2)特异性抗体
|
|
AU2019311102A1
(en)
|
2018-07-24 |
2021-02-25 |
Torque Therapeutics, Inc |
TLR7/8 agonists and liposome compositions
|
|
US11554120B2
(en)
|
2018-08-03 |
2023-01-17 |
Bristol-Myers Squibb Company |
1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
|
|
AU2019330977A1
(en)
|
2018-08-29 |
2021-04-15 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates targeting EGFR
|
|
US20210214354A1
(en)
|
2018-09-07 |
2021-07-15 |
Birdie Biopharmaceuticals, Inc. |
Imidazoquinoline compounds and uses thereof
|
|
AU2019337654A1
(en)
|
2018-09-12 |
2021-04-08 |
Silverback Therapeutics, Inc. |
Substituted benzazepine compounds, conjugates, and uses thereof
|
|
JP2022500414A
(ja)
|
2018-09-12 |
2022-01-04 |
シルバーバック セラピューティックス インコーポレイテッド |
免疫刺激性コンジュゲートにより疾患を処置する方法および組成物
|
|
WO2020056192A1
(en)
|
2018-09-12 |
2020-03-19 |
Silverback Therapeutics, Inc. |
Antibody conjugates of toll-like receptor agonists
|
|
WO2020056194A1
(en)
|
2018-09-12 |
2020-03-19 |
Silverback Therapeutics, Inc. |
Benzazepine compounds, conjugates, and uses thereof
|
|
EP3873532A1
(en)
|
2018-10-31 |
2021-09-08 |
Novartis AG |
Dc-sign antibody drug conjugates
|
|
EP3873938A1
(en)
|
2018-10-31 |
2021-09-08 |
Novartis AG |
Dc-sign antibody conjugates comprising sting agonists
|
|
HRP20230500T1
(hr)
|
2018-11-30 |
2023-07-21 |
Bristol-Myers Squibb Company |
Antitijelo koje sadrži c-terminalnu ekstenziju lakog lanca koja sadrži glutamin, njegovi konjugati, i postupci i primjene
|
|
KR20210102334A
(ko)
|
2018-12-12 |
2021-08-19 |
브리스톨-마이어스 스큅 컴퍼니 |
트랜스글루타미나제 접합을 위해 변형된 항체, 그의 접합체, 및 방법 및 용도
|
|
WO2020139618A1
(en)
|
2018-12-26 |
2020-07-02 |
Birdie Biopharmaceuticals, Inc. |
Immune modulatory combinations and methods for treating cancers
|
|
JP2022516308A
(ja)
|
2019-01-04 |
2022-02-25 |
アセンディス ファーマ オンコロジー ディヴィジョン エー／エス |
パターン認識受容体アゴニストのコンジュゲート
|
|
US20220089768A1
(en)
|
2019-01-04 |
2022-03-24 |
Trio Pharmaceuticals, Inc. |
Multi-specific protein molecules and uses thereof
|
|
JP7695885B2
(ja)
|
2019-02-12 |
2025-06-19 |
アンブルックス，インコーポレイテッド |
抗体－ｔｌｒアゴニストコンジュゲートを含有する組成物、その方法、及び使用
|
|
WO2020190734A1
(en)
|
2019-03-15 |
2020-09-24 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates targeting pd-l1
|
|
EP3937984A1
(en)
|
2019-03-15 |
2022-01-19 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates targeting her2
|
|
US20220226492A1
(en)
|
2019-03-15 |
2022-07-21 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates Targeting HER2
|
|
WO2020190762A1
(en)
|
2019-03-15 |
2020-09-24 |
Bolt Biotherapeutics, Inc. |
Macromolecule-supported tlr agonists
|
|
CN113811299A
(zh)
|
2019-03-15 |
2021-12-17 |
博笛生物科技有限公司 |
用于治疗癌症的免疫调控性组合物和方法
|
|
US20220152215A1
(en)
|
2019-03-15 |
2022-05-19 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates Targeting CEA
|
|
BR112021019950A2
(pt)
|
2019-04-05 |
2021-12-07 |
Dren Bio Inc |
Métodos de esgotamento de agentes causadores de doenças por meio de anticorpo de fagocitose alvejada
|
|
WO2020252015A1
(en)
|
2019-06-10 |
2020-12-17 |
Sutro Biopharma, Inc. |
Immunomodulator antibody drug conjugates and uses thereof
|
|
KR20220034784A
(ko)
|
2019-06-13 |
2022-03-18 |
볼트 바이오테라퓨틱스 인코퍼레이티드 |
아미노벤즈아제핀 화합물, 면역접합체, 및 이의 용도
|
|
CA3143156A1
(en)
|
2019-06-13 |
2020-12-17 |
Bolt Biotherapeutics, Inc. |
Macromolecule-supported aminobenzazepine compounds
|
|
US20220259202A1
(en)
|
2019-06-17 |
2022-08-18 |
Sutro Biopharma, Inc. |
1-(4-(aminomethyl)benzyl)-2-butyl-2h-pyrazolo[3,4-c]quinolin-4-amine derivatives and related compounds as toll-like receptor (tlr) 7/8 agonists, as well as antibody drug conjugates thereof for use in cancer therapy and diagnosis
|
|
US20220249685A1
(en)
|
2019-06-19 |
2022-08-11 |
Silverback Therapeutics, Inc. |
Anti-mesothelin antibodies and immunoconjugates thereof
|
|
US20210139477A1
(en)
|
2019-07-16 |
2021-05-13 |
Silverback Therapeutics, Inc. |
Alk5 inhibitors, conjugates, and uses thereof
|
|
US11339159B2
(en)
|
2019-07-17 |
2022-05-24 |
Pfizer Inc. |
Toll-like receptor agonists
|
|
TW202120500A
(zh)
|
2019-08-02 |
2021-06-01 |
美商梅爾莎納醫療公司 |
干擾素基因刺激蛋白（ｓｔｉｎｇ）激動劑化合物及用途
|
|
BR112022002720A2
(pt)
|
2019-08-15 |
2022-10-11 |
Silverback Therapeutics Inc |
Formulações de conjugados de benzazepinas e usos das mesmas
|
|
CA3148694A1
(en)
|
2019-09-03 |
2021-03-11 |
Romas Kudirka |
Aminoquinoline compounds, immunoconjugates, and uses thereof
|
|
JP2022547066A
(ja)
|
2019-09-04 |
2022-11-10 |
ボルト バイオセラピューティクス、インコーポレーテッド |
免疫結合体合成方法
|
|
CN114650844A
(zh)
|
2019-09-23 |
2022-06-21 |
西托姆克斯治疗公司 |
抗cd47抗体、可活化抗cd47抗体及其使用方法
|
|
WO2021067261A1
(en)
|
2019-09-30 |
2021-04-08 |
The Board Of Trustees Of The Leland Stanford Junior University |
Knottin-immunostimulant conjugates and related compositions and methods
|
|
AU2020359446A1
(en)
|
2019-09-30 |
2022-04-21 |
Bolt Biotherapeutics, Inc. |
Amide-linked, aminobenzazepine immunoconjugates, and uses thereof
|
|
WO2021067644A1
(en)
|
2019-10-01 |
2021-04-08 |
Silverback Therapeutics, Inc. |
Combination therapy with immune stimulatory conjugates
|
|
WO2021072203A1
(en)
|
2019-10-09 |
2021-04-15 |
Silverback Therapeutics, Inc. |
Tgfbetar1 inhibitor-asgr antibody conjugates and uses thereof
|
|
CA3154969A1
(en)
|
2019-10-25 |
2021-04-29 |
Romas Kudirka |
Macromolecule-supported thienoazepine compounds, and uses thereof
|
|
KR20220088901A
(ko)
|
2019-10-25 |
2022-06-28 |
볼트 바이오테라퓨틱스 인코퍼레이티드 |
티에노아제핀 면역접합체, 및 이의 용도
|
|
EP4069683A1
(en)
|
2019-12-06 |
2022-10-12 |
Mersana Therapeutics, Inc. |
Dimeric compounds as sting agonists
|
|
KR20220114049A
(ko)
|
2019-12-17 |
2022-08-17 |
화이자 인코포레이티드 |
Cd47, pd-l1에 특이적인 항체, 및 그의 용도
|
|
US20230101266A1
(en)
|
2019-12-31 |
2023-03-30 |
Genequantum Healthcare (Suzhou) Co., Ltd. |
Anti-trop2 antibodies, antibody-drug conjugates, and application of the same
|
|
US20230256108A1
(en)
|
2019-12-31 |
2023-08-17 |
Genequantum Healthcare (Suzhou) Co., Ltd. |
A drug conjugate and applications thereof
|
|
EP4093510A1
(en)
|
2020-01-21 |
2022-11-30 |
Bolt Biotherapeutics, Inc. |
Anti-pd-l1 antibodies
|
|
JP2023511363A
(ja)
|
2020-01-21 |
2023-03-17 |
ボルト バイオセラピューティクス、インコーポレーテッド |
坑ｐｄ－ｌ１抗体
|
|
US11179473B2
(en)
|
2020-02-21 |
2021-11-23 |
Silverback Therapeutics, Inc. |
Nectin-4 antibody conjugates and uses thereof
|
|
KR20220145871A
(ko)
|
2020-02-25 |
2022-10-31 |
볼트 바이오테라퓨틱스 인코퍼레이티드 |
암 치료 방법
|
|
WO2021202921A1
(en)
|
2020-04-01 |
2021-10-07 |
Altimmune Uk Limited |
Imidazoquinoline-type compounds and uses thereof
|
|
CN115955980A
(zh)
|
2020-04-10 |
2023-04-11 |
思进公司 |
电荷可变接头
|
|
CN115461122A
(zh)
|
2020-05-01 |
2022-12-09 |
博尔特生物治疗药物有限公司 |
抗dectin-2抗体
|
|
EP4146282A1
(en)
|
2020-05-08 |
2023-03-15 |
Bolt Biotherapeutics, Inc. |
Elastase-substrate, peptide linker immunoconjugates, and uses thereof
|